Obagi Medical Announces the Launch of Retinol + PHA Refining Night Cream
Obagi Medical, a subsidiary of Waldencast plc (NASDAQ: WALD) and the fastest-growing professional skincare brand in the U.S. in 2024, has launched its new Retinol + PHA Refining Night Cream. The $135 product combines Entrapped Retinol with Polyhydroxy Acid (PHA) Gluconolactone in a slow-release formula.
The clinical study demonstrated significant results after four weeks:
- 29% increase in skin smoothness
- 10% improvement in skin tone evenness
- 90% of users reported visibly smoother skin texture
- 90% observed reduced blemish appearance
The formula includes eight additional ingredients including Sodium Hyaluronate, Vitamin E, Squalane, and Glycerin. The product will be available through professional channels and on Obagi.com starting May 5, 2025.
Obagi Medical, una filiale di Waldencast plc (NASDAQ: WALD) e il marchio di skincare professionale in più rapida crescita negli Stati Uniti nel 2024, ha lanciato la sua nuova Retinol + PHA Refining Night Cream. Il prodotto da 135 dollari combina Retinolo incapsulato con Acido Poli-idrossi (PHA) Gluconolattone in una formula a rilascio lento.
Lo studio clinico ha mostrato risultati significativi dopo quattro settimane:
- Incremento del 29% nella levigatezza della pelle
- Miglioramento del 10% nell’uniformità del tono della pelle
- Il 90% degli utenti ha riportato una texture della pelle visibilmente più liscia
- Il 90% ha osservato una riduzione nell’aspetto delle imperfezioni
La formula contiene otto ingredienti aggiuntivi tra cui Sodio Ialuronato, Vitamina E, Squalano e Glicerina. Il prodotto sarà disponibile tramite canali professionali e su Obagi.com a partire dal 5 maggio 2025.
Obagi Medical, una subsidiaria de Waldencast plc (NASDAQ: WALD) y la marca de cuidado profesional de la piel de más rápido crecimiento en EE.UU. en 2024, ha lanzado su nueva Crema Nocturna Refinadora con Retinol + PHA. El producto de 135 dólares combina Retinol encapsulado con Ácido Poli-hidroxi (PHA) Gluconolactona en una fórmula de liberación lenta.
El estudio clínico demostró resultados significativos después de cuatro semanas:
- Aumento del 29% en la suavidad de la piel
- Mejora del 10% en la uniformidad del tono de piel
- El 90% de los usuarios reportaron una textura de piel visiblemente más suave
- El 90% observó una reducción en la apariencia de imperfecciones
La fórmula incluye ocho ingredientes adicionales, entre ellos Hialuronato de Sodio, Vitamina E, Escualano y Glicerina. El producto estará disponible a través de canales profesionales y en Obagi.com a partir del 5 de mayo de 2025.
오바지 메디컬은 월덴캐스트(Waldencast plc, NASDAQ: WALD)의 자회사이자 2024년 미국에서 가장 빠르게 성장하는 전문 스킨케어 브랜드로, 새로운 레티놀 + PHA 리파이닝 나이트 크림을 출시했습니다. 135달러 제품으로, 캡슐화된 레티놀과 폴리하이드록시산(PHA) 글루코노락톤을 느리게 방출하는 포뮬러에 결합했습니다.
임상 연구 결과 4주 후 다음과 같은 유의미한 효과가 나타났습니다:
- 피부 매끄러움 29% 증가
- 피부 톤 균일도 10% 개선
- 사용자의 90%가 눈에 띄게 부드러운 피부 질감을 보고
- 90%가 잡티 감소를 관찰
이 포뮬러에는 나트륨 히알루로네이트, 비타민 E, 스쿠알란, 글리세린 등 8가지 추가 성분이 포함되어 있습니다. 이 제품은 2025년 5월 5일부터 전문 채널과 Obagi.com에서 구매할 수 있습니다.
Obagi Medical, filiale de Waldencast plc (NASDAQ : WALD) et marque de soins professionnels pour la peau à la croissance la plus rapide aux États-Unis en 2024, a lancé sa nouvelle Crème de Nuit Affinante au Rétinol + PHA. Ce produit à 135 $ combine du Rétinol encapsulé avec de l’Acide Polyhydroxy (PHA) Gluconolactone dans une formule à libération lente.
L’étude clinique a démontré des résultats significatifs après quatre semaines :
- Augmentation de 29 % de la douceur de la peau
- Amélioration de 10 % de l’uniformité du teint
- 90 % des utilisateurs ont constaté une texture de peau visiblement plus lisse
- 90 % ont observé une réduction de l’apparence des imperfections
La formule comprend huit ingrédients supplémentaires, notamment du Hyaluronate de Sodium, de la Vitamine E, du Squalane et de la Glycérine. Le produit sera disponible via des canaux professionnels et sur Obagi.com à partir du 5 mai 2025.
Obagi Medical, eine Tochtergesellschaft von Waldencast plc (NASDAQ: WALD) und die am schnellsten wachsende professionelle Hautpflegemarke in den USA im Jahr 2024, hat ihre neue Retinol + PHA Refining Night Cream auf den Markt gebracht. Das 135-Dollar-Produkt kombiniert eingekapseltes Retinol mit Polyhydroxy-Säure (PHA) Gluconolacton in einer langsam freisetzenden Formel.
Die klinische Studie zeigte nach vier Wochen signifikante Ergebnisse:
- 29% Steigerung der Hautglätte
- 10% Verbesserung der Gleichmäßigkeit des Hauttons
- 90% der Anwender berichteten von sichtbar glatterer Hauttextur
- 90% beobachteten eine Verringerung des Hautunreinheiten-Erscheinungsbilds
Die Formel enthält acht weitere Inhaltsstoffe, darunter Natriumhyaluronat, Vitamin E, Squalan und Glycerin. Das Produkt wird ab dem 5. Mai 2025 über professionelle Kanäle und auf Obagi.com erhältlich sein.
- Fastest-growing professional skincare brand in U.S. in 2024
- Strong clinical trial results showing significant improvements in skin metrics
- Product expansion into growing skincare market
- Relatively high price point at $135 may limit market penetration
Insights
Obagi's new premium night cream strengthens Waldencast's portfolio with innovative technology targeting sensitive skin users with strong clinical results.
Obagi Medical's launch of Retinol + PHA Refining Night Cream represents a strategic product portfolio expansion for parent company Waldencast (NASDAQ: WALD). This
The clinical efficacy data is particularly compelling, with documented improvements including a
What's most significant from an investment perspective is the article's identification of Obagi as "the fastest-growing professional skincare brand in the U.S. in 2024," indicating strong momentum for this Waldencast subsidiary. The two-phase distribution strategy - launching first through professional channels before becoming available direct-to-consumer on May 5, 2025 - aligns with Obagi's professional brand identity while maximizing commercial reach.
For Waldencast's portfolio, this launch demonstrates R&D capabilities focused on clinically-validated solutions in the growing premium skincare segment. By addressing common barriers to retinol adoption (irritation and compliance issues), Obagi is potentially expanding its addressable market beyond traditional retinol users to include sensitive skin consumers - a significant demographic in skincare purchasing.
A Scientific Breakthrough in Skin Renewal: A Clinically Proven Dual-Action, Slow-Release, Overnight Skin Renewal Cream for a Resurfaced, Smoother, and More Even-Looking Complexion
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Obagi Medical ("Obagi"), the fastest-growing professional skincare brand in the U.S. in 2024* and a subsidiary of Waldencast plc, (NASDAQ: WALD) (“Waldencast”), proudly introduces its latest breakthrough: Retinol + PHA Refining Night Cream. This advanced formulation is engineered to optimize skin renewal by leveraging the efficacy of Entrapped Retinol with the scientifically proven gentle exfoliating properties of Polyhydroxy Acid (PHA) Gluconolactone. This synergistic combination enhances cell turnover while reinforcing the skin barrier, resulting in a visibly refined, smoother, and more even complexion.
Expanding on Obagi’s trusted retinol portfolio, this innovative formula incorporates PHA—a next-generation exfoliant with a larger molecular structure than Alpha Hydroxy Acids (AHAs) and Beta Hydroxy Acids (BHAs). This distinction allows for effective resurfacing with minimal irritation, making it ideal for individuals seeking to improve skin texture and tone while maintaining hydration and skin barrier integrity. Additionally, the formula features Entrapped Retinol, a slow-release delivery technology that gradually delivers retinol into multiple layers of the skin over time. This controlled release helps maximize efficacy while minimizing the irritation commonly associated with vitamin A products. The result is an effective yet gentle introduction to retinol, suitable for beginners and those with sensitive skin who may struggle with stronger retinoids.
“Patient compliance is the key to achieving visible results. By using a slow-release, encapsulated retinol combined with a gentle exfoliating and hydrating PHA, this formula makes it easier for patients to tolerate nightly use,” said Dr. Suzan Obagi, Chief Medical Director at Obagi. “As a result, they may experience improved skin texture and a noticeable reduction in blemishes.”
Retinol + PHA Refining Night Cream is fortified with eight additional dermatologically recognized ingredients to support hydration, minimize irritation, and enhance skin resilience. These ingredients include:
- Sodium Hyaluronate – A potent humectant that deeply hydrates and retains moisture.
- Vitamin E (Tocopherol) – A powerful antioxidant that shields against oxidative stress while nourishing the skin.
- Squalane – A bio-compatible lipid that enhances hydration, reinforces the skin barrier, and improves texture.
- Glycerin – A clinically proven hydrating agent that maintains moisture balance and supports skin resilience.
A four-week clinical study demonstrated the efficacy of Retinol + PHA Refining Night Cream, with participants experiencing significant improvements in skin texture and tone, including:
29% increase in skin smoothness*10% improvement in skin tone evenness*90% of users reporting visibly smoother skin texture*90% observing a reduction in the appearance of blemishes*
“At Obagi, our mission is to transform skin. We wanted to create a retinol solution that delivers real results while being accessible to those with sensitive skin, blemish concerns, or who aren’t ready for higher-strength retinoids," said Justin Giouzepis, Chief Marketing Officer of Obagi. "This formula was designed with both professionals and their patients in mind—addressing unmet needs with a gentle yet effective approach. We’re thrilled to report that our clinical data found that in just eight weeks, there was a 2.3x increase in the number of participants who felt comfortable in their own skin.”
The Retinol + PHA Refining Night Cream, priced at
*Results based on a 2024-2025 8-week clinical test. Data on file at Obagi Cosmeceuticals LLC.
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,* Obagi empowers individuals to achieve healthy, beautiful skin. The brand continues to lead in physician-recommended skincare solutions and is recognized as the #1 Physician-Recommended Brand for At-Home Skincare Products for Hyperpigmentation, Fine Lines & Wrinkles, and Sagging Skin & Loss of Elasticity.** More information about Obagi is available on the brand’s website, https://www.obagi.com.
*Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)
**According to Kline’s Physician- Dispensed Skin Care: U.S. Perception and Satisfaction Survey 2023.
About Waldencast
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. The first step in realizing its vision was the business combination with Obagi Cosmeceuticals and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset-light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com/.
Media Contact:
obagi@purplepr.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/19348f80-4f45-44c4-990a-dc3de7df67b7
FAQ
What are the key clinical results of Obagi's new Retinol + PHA Night Cream (WALD)?
When will Obagi's Retinol + PHA Night Cream be available for purchase?
How much does the new Obagi Retinol + PHA Night Cream cost?
What are the main active ingredients in Obagi's new night cream?
